Navigation Links
GlaxoSmithKline - Q2 Results and Strategy Update - Interview with CEO
Date:7/23/2008

LONDON, July 23 /PRNewswire-FirstCall/ -- In a video interview, new CEO Andrew Witty comments on GSK's second quarter results while also updating the market on his strategic vision for the business.
The new strategic priorities for GlaxoSmithKline are:

- Grow a diversified global business

- Deliver more products of value

- Simplify GSK's operating model

The interview, podcast and vodcast are available now on http://www.cantos.com. It's free to view. All you need to do is register at http://www.cantos.com. Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email enquiries@cantos.com or phone +44-207-936-1333. Cantos CEO interviews are also available on our CEO Insight page on iTunes.


'/>"/>
SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
2. CDC Immunization Advisory Committee Recommends Two New Pediatric Vaccines from GlaxoSmithKline
3. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
4. GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections
5. GlaxoSmithKline Signs Licensing Agreement With Compendia Bioscience
6. GlaxoSmithKline Named A Top Employer for Promoting Healthy Lifestyles
7. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
8. GlaxoSmithKline to Acquire Sirtris Pharmaceuticals, a World Leader in Sirtuin Research and Development
9. Pharmacopeia to Receive $5 Million Payment from GlaxoSmithKline
10. Ingenuity Systems Extends Enterprise-Level Software Agreement With GlaxoSmithKline
11. Vaccinex Antibody Licensed to GlaxoSmithKline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... launch of the Supplyframe Design Lab . Located in Pasadena, Calif., the ... future of how hardware projects are designed, built and brought to market. , ...
(Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
Breaking Biology Technology:
(Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
Breaking Biology News(10 mins):